Monograph Details
|
|
Neoplasms
> Antimetabolites
|
|
LEUSTATIN |
| Manufacturer |
|
Ortho Biotech Products, L.P. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Chlorinated purine nucleoside analog. |
| Generic Name |
|
Cladribine 1mg/mL; soln for IV infusion after dilution; preservative-free. |
| Indications |
|
Active hairy cell leukemia. |
| Children |
|
See literature. |
| Adults |
|
Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day. |
| Precautions |
|
Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended. |
| Interactions |
|
Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents. |
| Adverse Reactions |
|
Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare). |
| How Supplied |
|
Single-use vial (10mL)—7 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
